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Risk factors for COPD exacerbations in
inhaled medication users: the COPDGene
study biannual longitudinal follow-up
prospective cohort
Robert Busch1, MeiLan K. Han2, Russell P. Bowler3, Mark T. Dransfield4, J Michael Wells4, Elizabeth A. Regan3,
Craig P. Hersh1* and the COPDGene Investigators
Abstract
Background: Despite inhaled medications that decrease exacerbation risk, some COPD patients experience
frequent exacerbations. We determined prospective risk factors for exacerbations among subjects in the COPDGene
Study taking inhaled medications.
Methods: 2113 COPD subjects were categorized into four medication use patterns: triple therapy with tiotropium
(TIO) plus long-acting beta-agonist/inhaled-corticosteroid (ICS ± LABA), tiotropium alone, ICS ± LABA, and short-acting
bronchodilators. Self-reported exacerbations were recorded in telephone and web-based longitudinal follow-up
surveys. Associations with exacerbations were determined within each medication group using four separate logistic
regression models. A head-to-head analysis compared exacerbation risk among subjects using tiotropium vs. ICS ±
LABA.
Results: In separate logistic regression models, the presence of gastroesophageal reflux, female gender, and higher
scores on the St. George’s Respiratory Questionnaire were significant predictors of exacerbator status within multiple
medication groups (reflux: OR 1.62–2.75; female gender: OR 1.53 - OR 1.90; SGRQ: OR 1.02–1.03). Subjects taking either
ICS ± LABA or tiotropium had similar baseline characteristics, allowing comparison between these two groups. In the
head-to-head comparison, tiotropium users showed a trend towards lower rates of exacerbations (OR = 0.69 [95 % CI 0.45,
1.06], p = 0.09) compared with ICS ± LABA users, especially in subjects without comorbid asthma (OR = 0.56 [95 % CI 0.31,
1.00], p = 0.05).
Conclusions: Each common COPD medication usage group showed unique risk factor patterns associated with
increased risk of exacerbations, which may help clinicians identify subjects at risk. Compared to similar subjects using
ICS ± LABA, those taking tiotropium showed a trend towards reduced exacerbation risk, especially in subjects without
asthma.
Trial registration: ClinicalTrials.gov NCT00608764, first received 1/28/2008.
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Background
The frequency of exacerbations defines a distinct pheno-
type of COPD and has implications for prognosis and pos-
sibilities for intervention [1]. COPD exacerbations impact
the morbidity, mortality, and clinical course of COPD
[2–7]. Previous studies examined the association of COPD
severity and the frequency of acute exacerbations in an
effort to accurately characterize this subset of patients [1].
Additionally, chest computed tomography (CT) features
such as bronchial wall thickness [8], emphysema percent-
age [8], and ratio of pulmonary artery diameter to aortic
diameter [9] identify patients susceptible to exacerbations.
These studies did not consider differences in medication
use and the relationship to exacerbation frequency.
Some commonly prescribed medications have been
shown to decrease the rate of exacerbations in randomized
clinical trials, including tiotropium (TIO) [10] and long-
acting beta-agonists/inhaled corticosteroid (ICS ± LABA)
combinations [11]. The relative merits of these two therap-
ies have been compared through a meta-analysis [12] as
well as a randomized trial [13]. Although these studies have
provided evidence regarding COPD treatment, there still
remains a subset of patients who experience frequent exac-
erbations despite appropriate therapy. It is unclear what
factors separate medication non-responders from those
who respond more favorably to inhaled medications such
as short-acting bronchodilators (SAB), ICS ± LABA, long-
acting muscarinic antagonists, or combinations of these
medications.
The Genetic Epidemiology of COPD Study (COPDGene,
clinicaltrials.gov identifier NCT00608764) is a large obser-
vational study of smokers with and without COPD [14].
We examined the differences between COPD subjects with
and without exacerbations stratified by common medica-
tion use patterns using four separate logistic regression
models, analyzing risk factors within each medication usage
group to minimize confounding by indication. The primary
hypothesis was that unique risk factor profiles for the
exacerbator phenotype would exist for subjects on different
inhaled medications. In a separate head-to-head analysis,
we examined the effect of tiotropium vs. long-acting beta-
agonist/inhaled corticosteroids on exacerbation risk.
Methods
COPDGene is an observational study of COPD conducted
at 21 clinical centers in the U.S. (see Additional file 1:
Supplementary Data and Methods) designed to discover
epidemiologic and genetic risk factors for COPD [8, 14,
15]. It consists of 10,192 current and former Non-Hispanic
white or African-American smokers with and without
COPD. Each subject underwent spirometry, inspiratory and
expiratory chest CT scans, and questionnaires related to
demographics, medical history, symptoms and quality of
life, in addition to blood samples for genetic analysis. The
Longitudinal Follow-Up (LFU) program is a prospective
follow-up program [16] in COPDGene using automated
telephone and web-based surveys every 3–6 months to
monitor incident exacerbations, comorbidities, and death
[15]. The LFU dataset (version Oct 12, 2013) used for this
investigation included 8465 subjects with a mean follow-up
time of 3.35 years. An exacerbation was defined as an epi-
sode of increased cough, phlegm, or shortness of breath
that lasted >48 h and required treatment with antibiotics,
systemic steroids, or both. Severe exacerbations required an
emergency room visit or hospitalization. Asthma was de-
fined by self-report of a doctor’s diagnosis of asthma be-
fore age 40, as previously reported [17]. The COPDGene
Study was approved by Partners Healthcare institutional
review board (Protocol # 2007P000554) and institutional
review boards at all study sites, and written informed
consent was obtained from all subjects. This study was
conducted in accordance with the amended Declaration
of Helsinki. The St. George's Respiratory Questionnaire
was used with permission.
This analysis included subjects with COPD defined by a
forced expiratory volume in one second (FEV1) to forced
vital capacity (FVC) ratio <0.7 (GOLD stages 1–4) [18].
Subjects without LFU data and subjects not using inhaled
medications were excluded, leaving 2543 subjects. Four
medication usage patterns (Fig. 1) were defined at the
baseline study visit: 1) Triple therapy with long-acting
beta-agonist/inhaled corticosteroid and tiotropium (TIO/
LABA/ICS, N = 863); 2) tiotropium alone (TIO, N = 256);
3) long-acting beta-agonists/inhaled corticosteroid or
inhaled corticosteroid alone (ICS ± LABA, N = 628); 4)
short-acting bronchodilator medications only (SAB,
N = 366), including albuterol or ipratropium alone or
in combination.
Subjects with an exacerbation rate of one or more per
year in the LFU were considered exacerbators, those with
no exacerbations were considered non-exacerbators, and
those with between zero and one exacerbation per year
were not classified. The previously described threshold of
greater than two exacerbations per year [1] resulted in an
insufficient sample size for the subgroup analyses (Fig. 2).
Statistical analysis was performed using R software [19].
Additional methods are available in the online supple-
ment (see Additional file 1: Supplementary Data and
Methods).
Within medication group analysis
We compared exacerbators versus non-exacerbators within
each medication group for differences in imaging character-
istics, symptoms, comorbidities, pulmonary function tests,
and demographics. Univariate analysis of binary variables
was performed using chi-square statistics and continuous
variables using Student's T-test. Significant prospective uni-
variate risk factors were used to build multivariable logistic
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regression models including a group of common covariates
(age, race, gender, FEV1 % predicted).
Head-to-head analysis
We examined the effect of tiotropium vs long-acting beta-
agonist/inhaled corticosteroid on exacerbator phenotype
in a logistic regression model using a combined subject
pool of the TIO and ICS ± LABA medication groups, who
were shown to have similar baseline characteristics.
Covariates included baseline differences between the
groups. The analysis was repeated after stratification
for comorbid asthma.
Fig. 1 Study subjects. The COPDGene cohort was narrowed to those with LFU data available, then narrowed to subjects with a diagnosis of
COPD by GOLD criteria, then to those taking medications. These subjects were divided into four exclusive groups based on medication use, as
defined in the Methods section. Exacerbators had one or more exacerbations per year, non-exacerbators had zero exacerbations per year, subjects
with between 0 and 1 exacerbations per year were not classified. LFU = Longitudinal follow-up; FEV1/FVC = ratio of forced expiratory volume in
one second to forced vital capacity
Fig. 2 Frequency of COPD exacerbations within the four medication groups. Medication groups are mutually exclusive. TIO/LABA/ICS indicates
triple therapy with tiotropium, long-acting beta-agonist/inhaled corticosteroid, TIO indicates tiotropium alone, ICS ± LABA indicates long-acting
beta-agonist/inhaled corticosteroid combination therapy, and SAB indicates short-acting bronchodilators alone
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Results
Baseline characteristics
The TIO/LABA/ICS group showed a higher percentage of
subjects on oxygen therapy, shorter six minute walk test
(6MWT) distance, lower FEV1, higher Modified Medical
Research Council dyspnea (MMRC) score, higher total
SGRQ score, higher BODE (body mass index, airflow ob-
struction, dyspnea, and exercise capacity) score, and greater
percent emphysema and gas trapping compared to the
other groups (Table 1), similar to data previously published
by Park et al. [20]. In addition, they showed higher rates of
exacerbations/year (1.1) and severe exacerbations/year (0.4)
in LFU. These features describe a sicker population with
worse functional measures, higher symptom scores, and
more disease on chest CT scans.
The ICS ± LABA and TIO groups showed broad simi-
larities in baseline characteristics (Table 2). They did not
significantly differ in functional measures such as 6MWT
distance and FEV1, rates of comorbidities such as GERD,
nor in imaging characteristics such as emphysema and gas
trapping. Several of the variables, including MMRC score,
SGRQ score, and BODE score, showed small statistically
significant differences that may not be clinically significant
based on accepted standards. The differences in TLC
Table 1 Baseline characteristics: COPD subjects included in the longitudinal follow-up data, stratified by medication groups
All COPD subjects Chronic oral steroids TIO/LABA/ICS TIO ICS ± LABA SAB
N = 3828 174 863 256 628 366
Gender (female) 2091 (52 %) 87 (50 %) 447 (52 %) 120 (47 %) 305 (49 %) 218 (60 %)
Race (African-American) 736 (19 %) 50 (29 %) 155 (18 %) 35 (14 %) 112 (18 %) 92 (25 %)
Oxygen Therapy 948 (36 %) 87 (50 %) 455 (53 %) 71 (28 %) 165 (26 %) 57 (16 %)
Chronic Bronchitis 968 (30 %) 52 (30 %) 242 (28 %) 65 (25 %) 186 (30 %) 128 (35 %)
Doctor's Diagnosis of Asthma 918 (32 %) 71 (41 %) 271 (31 %) 41 (16 %) 247 (39 %) 107 (29 %)
Frequent Cough Symptom 1597 (47 %) 87 (50 %) 369 (43 %) 118 (46 %) 289 (46 %) 204 (56 %)
Frequent Phlegm Symptom 1739 (52 %) 107 (61 %) 420 (49 %) 115 (45 %) 328 (52 %) 209 (57 %)
Hay Fever 1156 (33 %) 69 (40 %) 263 (30 %) 79 (31 %) 235 (37 %) 113 (31 %)
GERD 1142 (34 %) 54 (31 %) 313 (36 %) 85 (33 %) 220 (35 %) 114 (31 %)
Cardiovascular Disease 748 (22 %) 31 (18 %) 197 (23 %) 63 (25 %) 129 (21 %) 83 (23 %)
Age (years) 63.8 ± 8.3 63.7 ± 8.6 64.5 ± 7.7 66.3 ± 8.1 64.6 ± 8.5 62.5 ± 8.6
Pack Years of Smoking 51.7 ± 28 51.5 ± 29 54.1 ± 26 53.5 ± 28 52.8 ± 30 54.3 ± 29
Current Smoking 1486 (39 %) 42 (24 %) 188 (22 %) 88 (34 %) 202 (32 %) 202 (55 %)
6MWT distance (ft) 1250 ± 380 943 ± 400 1068 ± 350 1216 ± 320 1206 ± 390 1212 ± 370
FEV1 percent predicted 57.2 ± 20 39.3 ± 19 41.7 ± 17 54.4 ± 19 53.1 ± 20 56.1 ± 19
FEV1/FVC 0.52 ± 0.13 0.43 ± 0.12 0.43 ± 0.12 0.49 ± 0.11 0.50 ± 0.13 0.53 ± 0.12
GOLD 1 660 (17 %) 6 (3 %) 21 (2 %) 23 (9 %) 60 (10 %) 44 (12 %)
GOLD 2 1634 (43 %) 37 (21 %) 238 (28 %) 120 (47 %) 275 (44 %) 174 (47 %)
GOLD 3 1022 (27 %) 67 (39 %) 364 (42 %) 84 (33 %) 209 (33 %) 116 (32 %)
GOLD 4 512 (13 %) 64 (37 %) 240 (28 %) 29 (11 %) 84 (13 %) 32 (9 %)
MMRC Score 1.9 ± 1.3 3.0 ± 1.1 2.8 ± 1.1 2.0 ± 1.2 2.3 ± 1.3 2.0 ± 1.4
SGRQ Total Score 36.2 ± 19 57.2 ± 17 49.1 ± 18 38.9 ± 17 42.6 ± 20 41.9 ± 20
BODE score 2.5 ± 1.9 4.4 ± 1.9 4.0 ± 1.7 2.6 ± 1.7 2.9 ± 1.9 2.6 ± 1.8
TLC by CT percent predicted 102.3 ± 17 104.5 ± 17 106.1 ± 18 101.9 ± 15 104.3 ± 17 100.4 ± 16
SRWA-Pi10 3.70 ± 0.14 3.76 ± 0.13 3.72 ± 0.14 3.70 ± 0.14 3.73 ± 0.15 3.74 ± 0.16
Percent Emphysema 12.0 ± 13 18.4 ± 14 19.5 ± 14 12.7 ± 10 12.7 ± 12 8.8 ± 9.4
Percent Gas Trapping 36.4 ± 20 47.7 ± 20 48.7 ± 19 39.0 ± 17 39.3 ± 20 33.8 ± 20
BMI (kg/m^2) 28.0 ± 6.4 27.9 ± 6.3 27.8 ± 6.3 27.8 ± 6.1 28.4 ± 6.5 28.8 ± 7.1
Exacerbations/Year in Follow-Up 0.7 ± 1.4 1.5 ± 2.0 1.1 ± 1.7 0.5 ± 0.9 0.7 ± 1.1 0.6 ± 1.1
Severe Exacerbations/Year 0.2 ± 0.8 0.6 ± 1.3 0.4 ± 0.9 0.1 ± 0.3 0.2 ± 0.6 0.2 ± 0.6
Mean (SD) or N (%) are shown. See Methods for group definitions. N (%) or Mean ± SD are shown
TIO Tiotropium, ICS ± LABA long-acting beta-agonist/inhaled corticosteroid, SAB short-acting bronchodilator, 6MWT six minute walk test distance, TLC total lung
capacity, CT computed tomography, FEV forced; expiratory volume in one second, GERD gastroesophageal reflux disease, SRWA-Pi10 square root wall; area of a
10 mm airway, BMI body mass index
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(101.9 % in TIO vs. 104.3 % in ICS ± LABA) and SRWA-
Pi10 (3.70 mm in TIO vs. 3.73 mm in ICS ± LABA) are
also small. However, there were differences in the propor-
tion of subjects with asthma (16.0 % in TIO vs. 39.3 % in
ICS ± LABA) and the mean exacerbation rates (0.5 per
year in TIO vs. 0.7 per year in ICS ± LABA). When
subjects with asthma were removed, the differences in
exacerbation rates, SRWA-Pi10, and SGRQ were no
longer significant (see Additional file 1: Supplementary
Data and Methods 1, Table S1 and S2).
The SAB group contained 366 subjects (Table 1), with
the best lung function (FEV1 56.1 % predicted) and one
of the lowest exacerbation rates (0.6 per year). Despite
this, 148 (40 %) of SAB subjects had GOLD stage 3 or 4
disease. In addition, 80 (22 %) SAB subjects had greater
than one exacerbation per year, while 31 (8.5 %) had two
or more exacerbations per year. There was a higher
proportion of African-Americans than in other groups,
and the SAB group had the highest proportion with
chronic bronchitis. Functional measurements such as
6MWT were better compared with other groups, and
they had the least emphysema.
The 174 subjects on chronic oral steroids tended to
have lower lung function (FEV1 39.3 % predicted) and
an exacerbation rate (1.6 per year) that was comparable
to other groups despite use of chronic systemic steroids.
Subjects on chronic oral steroids in COPDGene have
been described previously [21].
Within medication group analysis
In univariate analysis, risk factors for the exacerbator
phenotype were discovered within each medication
group (see Additional file 1: Supplementary Data and
Methods 1, Table S3). Notable risk factors consistent
across all medication groups were frequent cough symp-
toms and higher TLC. GERD, asthma, and higher SGRQ
score were statistically significant risk factors of exacer-
bator status in the TIO/LABA/ICS, TIO, and ICS ±
LABA groups, but not in the SAB group. The presence
of chronic bronchitis and of daily phlegm symptoms
were not significant predictors in subjects taking tiotro-
pium (TIO/LABA/ICS and TIO groups), but were pre-
dictors in subjects not taking tiotropium (ICS ± LABA
and SAB groups). Similarly, emphysema on CT was pre-
dictive of exacerbator phenotype only in subjects not re-
ceiving tiotropium. Bronchodilator (BD) responsiveness
as measured by absolute change in FEV1 was not a sig-
nificant risk factor in subjects receiving ICS ± LABA
combinations (with or without TIO), but was a signifi-
cant risk factor in subjects without ICS ± LABA (TIO
and SAB groups). Prior venous thromboembolism, ob-
structive sleep apnea, higher body mass index (BMI),
and congestive heart failure were not associated with
exacerbator phenotype. Current smoking status was not
a risk factor in any medication group, nor was lifetime
smoking exposure, measured in pack-years (Additional
file 1: Supplementary Data and Methods, Table S3).
Logistic regression was performed within each medica-
tion group using the significant univariate risk factors as
covariates, in addition to age, race, sex, and FEV1 (Table 3).
Risk factors of female gender, higher SGRQ score, prior
pneumonia, and GERD remained significant in the TIO/
LABA/ICS group, while the presence of co-morbid asthma
showed a trend towards significance. Younger age, asthma,
greater gas-trapping by CT, and GERD were statistically
significant risk factors in the TIO group, while female
gender and African-American race approached significance.
Female gender, higher SGRQ score, and GERD were risk
factors in the ICS ± LABA group, while history of pneumo-
nia, hay fever, and cardiovascular disease all approached
statistical significance. In the SAB group, female gender,
Table 2 Baseline characteristics: comparison of COPD subjects
within the tiotropium or long acting beta-agonists/inhaled
corticosteroid groups
TIO ICS ± LABA p-value
Gender (female, %) 46.9 48.6 0.7
Race (Non-Hispanic White, %) 86.3 82.2 0.2
Oxygen Therapy (%) 27.7 26.3 0.7
Chronic Bronchitis (%) 25.4 29.6 0.2
Doctor's Diagnosis of Asthma (%) 16.0 39.3 <0.001
Frequent Cough Symptom (%) 46.1 46.0 1.0
Frequent Phlegm Symptom (%) 44.9 52.2 0.06
Hay Fever (%) 30.9 37.4 0.2
GERD (%) 33.2 35.0 0.7
Cardiovascular disease (%) 24.6 20.5 0.2
Age (years) 66.3 64.6 0.006
Current Smoking 34.4 32.2 0.6
Pack-Years of Smoking 53.5 52.8 0.7
6MWT distance (ft) 1216 1206 0.7
FEV1 percent predicted 54.4 53.1 0.3
FEV1/FVC 0.49 0.50 0.5
MMRC Score 2.0 2.3 0.006
SGRQ Total Score 38.9 42.6 0.007
BODE score 2.6 2.9 0.02
TLC by CT percent predicted 101.9 104.3 0.04
SRWA-Pi10 3.70 3.73 0.003
Percent Emphysema 12.7 12.7 1.0
Percent Gas Trapping 39.0 39.3 0.8
BMI (kg/m^2) 27.8 28.4 0.2
Exacerbations/Year in Follow-Up 0.5 0.7 0.004
Means or percentages are shown. P-values < 0.05 are in bold
6MWT six minute walk test, TLC total lung capacity, CT computed tomography,
FEV1 forced expiratory volume in one second, BD bronchodilator, GERD
gastroesophageal reflux disease, BMI body mass index
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Table 3 Within medication group analysis: logistic regression models for the exacerbator phenotype
Odds ratio Lower CI Upper CI p-value
A. Tiotropium/Inhaled corticosteroid/Long acting beta-agonist
Age, years 0.98 0.95 1.00 0.1
Female Gender 1.53 1.05 2.21 0.03
African-American Race 0.69 0.44 1.09 0.1
FEV1 Percent Predicted 1.00 0.98 1.02 0.9
TLC by CT percent predicted 1.01 0.99 1.02 0.3
SGRQ Total Score 1.02 1.00 1.03 0.02
MMRC Score 0.85 0.60 1.21 0.4
BODE Score 1.08 0.80 1.47 0.6
Frequent Cough Symptom 1.11 0.75 1.64 0.6
Doctor's Diagnosis of Asthma 1.19 0.98 1.45 0.08
Hay Fever 1.01 0.81 1.27 0.9
Prior Pneumonia 1.36 1.03 1.80 0.03
GERD 1.62 1.11 2.38 0.01
B. Tiotropium
Age, years 0.93 0.87 1.00 0.04
Female Gender 2.64 0.95 7.33 0.06
African-American Race 0.15 0.02 1.28 0.08
FEV1 percent predicted 1.02 0.99 1.06 0.1
FEV1 change with bronchodilator (L) 2.99 0.10 87.43 0.5
TLC by CT percent predicted 1.00 0.97 1.04 0.9
Percent Gas Trapping 1.06 1.02 1.11 0.01
SGRQ Total Score 1.01 0.98 1.04 0.4
Frequent Cough Symptom 1.69 0.64 4.47 0.3
Doctor's Diagnosis of Asthma 1.57 1.06 2.32 0.03
GERD 2.75 1.10 6.88 0.03
C. Long acting beta-agonist/inhaled corticosteroid
Age, years 1.00 0.96 1.03 0.8
Female Gender 1.90 1.19 3.05 0.01
African-American Race 0.71 0.39 1.29 0.3
FEV1 percent predicted 0.98 0.96 1.01 0.1
Resting Oxygen Saturation (%) 0.97 0.90 1.04 0.4
6MWT distance 1.00 1.00 1.00 0.5
FEV1 change with bronchodilator (L) 1.65 0.42 6.39 0.5
TLC by CT percent predicted 1.01 0.99 1.02 0.3
Percent Emphysema 1.02 0.99 1.04 0.2
MMRC Score 1.04 0.71 1.54 0.8
SGRQ Total Score 1.03 1.01 1.04 0.01
BODE Score 0.96 0.68 1.35 0.8
Frequent Cough Symptom 1.50 0.91 2.45 0.1
Doctor's Diagnosis of Asthma 1.00 0.77 1.29 1.0
Hay Fever 1.27 0.98 1.66 0.07
Prior pneumonia 1.35 0.99 1.84 0.06
GERD 1.96 1.21 3.15 0.01
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home oxygen therapy, and frequent cough symptom were
all statistically significant risk factors, while higher FEV1
change post-BD approached statistical significance. Statisti-
cally significant results are summarized in Table 4.
Head-to-head analysis
In the analysis of each group’s baseline characteristics,
we determined that the TIO and ICS ± LABA groups
represented broadly similar populations of subjects in
terms of severity, imaging characteristics, and symptoms.
These similarities allowed us to combine these groups to
analyze exacerbation risk factors in a head-to-head fash-
ion while limiting confounding by indication. We com-
pared the effects of tiotropium vs. ICS ± LABA therapy
on prospective exacerbations in a logistic regression
model combining subjects in the TIO and ICS ± LABA
groups (Table 5) adjusted for the baseline differences be-
tween the groups, including age, asthma, MMRC score,
SGRQ score, BODE score, and TLC. There was a trend
towards a reduction in exacerbation risk for tiotropium
(OR 0.69, p = 0.09). The logistic regression models were
repeated after stratifying by asthma status. In subjects
without a history of comorbid asthma, there was a
stronger trend toward reduction in exacerbation risk
from tiotropium (OR 0.56, p = 0.05). In only the subjects
with comorbid asthma, this association disappeared (OR
1.03, p = 1.0).
Discussion
Using prospective observational data from the COPDGene
Study, we identified risk factors for exacerbations within
four groups of subjects with common medication use
patterns. While comparison across medication groups is
confounded by indication, we found substantial similar-
ities between the subjects using ICS ± LABA and those
using TIO. Controlling for baseline differences in a head-
to-head analysis, we saw a trend towards an association
with reduced exacerbation risk for tiotropium compared
to ICS ± LABA, especially in subjects without the diagno-
sis of asthma. We also demonstrated the feasibility of
using self-reported medication data from an observational
study to generate hypotheses regarding drug treatment
effects.
The interplay of comorbid conditions with COPD ex-
acerbations has been previously described [22, 23], and
the influence of comorbidities on COPD exacerbations
is also shown in our study. Respiratory comorbidities
such as asthma and prior pneumonia were risk factors in
some groups. GERD has previously been described as a
risk factor for more frequent COPD exacerbations [24]
Table 3 Within medication group analysis: logistic regression models for the exacerbator phenotype (Continued)
Cardiovascular disease 1.68 0.96 2.91 0.07
D. Short acting bronchodilators
Age, years 1.01 0.97 1.05 0.8
Female Gender 2.56 1.30 5.03 0.01
African-American Race 0.53 0.23 1.21 0.1
FEV1 percent predicted 0.98 0.96 1.01 0.1
Oxygen Therapy 2.47 1.11 5.51 0.03
FEV1 change with bronchodilator (L) 5.60 0.97 32.41 0.05
TLC by CT percent predicted 1.00 0.98 1.03 0.7
Percent Emphysema 1.03 0.99 1.08 0.2
BODE Score 1.00 0.78 1.28 1.0
Frequent Cough Symptom 2.14 1.13 4.06 0.02
Hay Fever 1.19 0.86 1.64 0.3
Prior Pneumonia 1.08 0.75 1.56 0.7
P-values <0.05 are in bold
Table 4 Within medication group analysis: summary of
exacerbation risk factors by medication group
TIO/LABA/ICS TIO ICS ± LABA SAB
Younger Age (years) +
Doctor's Diagnosis of Asthma / +
Frequent Cough Symptom +
Female Gender + / + +
GERD + + +
Oxygen Therapy +
Higher Percent Gas Trapping +
Prior Pneumonia + /
Higher SGRQ Total Score + +
(+) indicates that the variable was a statistically significant predictor of
exacerbator status in the corresponding medication group (see Table 3). (/)
indicates that the variable approached statistical significance (p < 0.1).
Direction of association is noted in the variable text
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and our data showed a similar effect in all medication
groups except for those using only short-acting agents.
Notably, other cardiopulmonary comorbidities such as
prior venous thromboembolism, obstructive sleep apnea,
higher BMI, and congestive heart failure did not show
an association. Previous studies have shown an associ-
ation between ongoing smoking and exacerbation risk
[25–27]. However, current smoking and cumulative
pack-year exposure were not risk factors in any group
within our study, despite the acute [28] and chronic
inflammatory effects of cigarette smoke on airways [29]
and the immune system [30].
The baseline characteristics of the TIO and ICS ± LABA
groups were similar across many clinical parameters.
Although SGRQ and MMRC scores were statistically
different between the two groups, these did not exceed
thresholds for minimal clinically important differences
[31, 32]. The similarities between these baseline charac-
teristics make possible comparison between the two
groups with less concern of confounding by indication.
The similarity between the two groups was more clearly
seen among the non-asthmatic subjects. These findings
reflect current clinical practice guidelines, in which
administration of a long-acting beta-agonist/inhaled
corticosteroid or long-acting muscarinic-antagonist are
both recommended for patients with FEV1 < 60 %
predicted and stable symptoms [33]. The overall rate of
exacerbations among this population was lower than
previously published randomized controlled trials data of
TIO [3, 13] or ICS ± LABA [13], however those trials
enrolled patients with more severe airflow obstruction.
The number of subjects with asthma in the ICS ±
LABA group was higher than in the TIO group. It is
plausible that concurrent asthma may lead a provider to
prescribe ICS ± LABA combinations [34] given the
prominent role of inhaled corticosteroids as anti-
inflammatory therapy in asthma [35]. Alternatively, sub-
jects with asthma and COPD may have had greater
symptomatic response to ICS ± LABA, creating a prefer-
ence for this medication among asthma-COPD overlap
patients. In previous COPDGene publications, the
asthma-COPD overlap syndrome has been shown to be
a relevant clinical entity, associated with worse health-
related quality of life and more frequent exacerbations
[17, 36]. These findings were recapitulated in our
analysis, with subjects with asthma-COPD overlap taking
Table 5 Head-to-head analysis: logistic regression models for the effect of tiotropium vs. long-acting beta-agonist/inhaled corticosteroid
on exacerbator status
Odds ratio Lower CI Upper CI p-value
A. All subjects using either TIO or ICS ± LABA (N = 602)
Tiotropium Usage 0.69 0.45 1.06 0.09
Doctor's Diagnosis of Asthma 1.22 1.01 1.47 0.04
Age (years) 1.00 0.98 1.02 1.0
MMRC Score 0.97 0.75 1.25 0.8
SGRQ Total Score 1.03 1.01 1.04 <0.001
BODE Score 1.08 0.92 1.26 0.4
TLC by CT percent predicted 1.02 1.00 1.03 0.01
B. Excluding subjects with doctor diagnosed asthma (N = 341)
Tiotropium Usage 0.56 0.31 1.00 0.05
Age (years) 1.00 0.96 1.03 0.9
MMRC Score 1.03 0.70 1.50 0.9
SGRQ Total Score 1.04 1.01 1.06 <0.001
BODE Score 0.96 0.77 1.21 0.8
TLC by CT percent predicted 1.02 1.00 1.04 0.02
C. Only subjects with doctor diagnosed asthma (N = 198)
Tiotropium Usage 1.03 0.39 2.70 1.0
Age (years) 1.01 0.97 1.05 0.6
MMRC Score 0.89 0.59 1.35 0.6
SGRQ Total Score 1.02 1.00 1.04 0.06
BODE Score 1.21 0.94 1.57 0.1
TLC by CT percent predicted 1.01 0.99 1.03 0.2
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either TIO or ICS ± LABA showing a higher rate of exac-
erbations than their non-asthmatic counterparts, as well
as a trend towards higher SGRQ scores.
In this observational study, we observed a trend towards
an association with reduction in exacerbation risk in sub-
jects taking tiotropium compared to ICS ± LABA. The
trend was stronger in subjects without asthma. Conflicting
randomized trial literature exists on the choice of tiotro-
pium or long-acting beta-agonist/inhaled corticosteroid in
advanced stage COPD. The INSPIRE trial [13] showed no
difference in rates of exacerbations among COPD subjects
randomized to ICS ± LABA vs. TIO, and subjects were
excluded from INSPIRE if they had significant bronchodila-
tor response or asthma [37]. However INSPIRE subjects
had more severe airflow obstruction (mean FEV1 39.3 %
predicted vs. 48.3 % predicted in our study), so their com-
parison of TIO and ICS/LABA may not generalize to
COPDGene. Conversely, a recent meta-analysis of random-
ized controlled trials comparing tiotropium vs. long-acting
beta-agonist (with 35–56 % of patients taking inhaled
corticosteroid as well) in stable COPD showed a reduction
in exacerbations with tiotropium.
Previous literature comparing COPD medication regi-
mens with and without inhaled corticosteroids have
largely focused on comparisons of LABA alone versus
ICS + LABA, without comparisons of long-acting musca-
rinics versus an ICS ± LABA regimen. A randomized
trial conducted in Canada in subjects with moderate to
severe COPD showed a decreased exacerbation rate in
subjects receiving fluticasone as part of a triple therapy
regimen of tiotropium/fluticasone/salmeterol compared
with those receiving tiotropium alone or tiotropium/sal-
meterol [38]. The TORCH trial [11] showed a decreased
annual exacerbation rate in subjects with moderate to
severe COPD receiving fluticasone/salmeterol therapy
compared with those receiving salmeterol alone. More
recently, the WISDOM trial [39] demonstrated that the
time to first moderate or severe COPD exacerbation was
similar in subjects with severe and very severe COPD
continuing triple therapy with tiotropium/salmeterol/flu-
ticasone or undergoing controlled withdrawal of inhaled
corticosteroid therapy, which cast doubt on the added
benefit of corticosteroids for those with stable COPD.
Finally, the longitudinal cohort study by Gershon et al.
from 2014 [40] reviewed database information in elderly
COPD subjects without asthma starting LABA or ICS ±
LABA therapy and showed that those subjects using
LAMAs did not have a better outcome on the composite
outcome of hospitalization or death. Given the conflict-
ing evidence regarding the optimal choice of inhaled
therapy for patients with moderate to severe COPD, we
contend that our data adds to the debate questioning
the added benefit of inhaled corticosteroids in these
patients, and is hypothesis-generating for additional
investigation comparing ICS ± LABA versus tiotropium
alone.
Our study has several limitations. The medication usage
data is based upon subject report at the initial study visit,
and was not updated during the longitudinal follow-up.
Because of the lack of follow-up medication data, we are
unable to account for medication changes that might
influence inclusion and analysis of a subject in a particular
medication group. Self-report of exacerbations could
introduce bias, however this self-reported definition has
been used in previous work in COPDGene as well as other
COPD studies such as ECLIPSE [1]. LFU calls were com-
pleted every 3 to 6 months, so some exacerbation events
may have been missed. Therefore we dichotomized sub-
jects into exacerbators and non-exacerbators, rather than
analyzing exacerbation counts. Our definition of exacerba-
tors used a threshold of ≥1 exacerbation per year, which
differs from previous studies which used ≥2 exacerbations
per year [1] and may limit direct comparison of results.
COPDGene subjects had a lower overall rate of exacerba-
tions than other study populations. Using a threshold of
≥2 exacerbations per year led to small sample sizes in the
medication groups (see Fig. 2) that would have limited our
power to detect associations. The definition of asthma in
this study was based on self-reported diagnosis by a
clinician, which has been previously used in COPDGene
[17]. The diagnosis of asthma may have influenced a
prescriber’s choice of inhaled corticosteroids as a control-
ler medication. In order to minimize confounding by indi-
cation, we compared exacerbation risk factors within
subjects reporting the same medication usage pattern.
The characteristics of subjects using TIO and ICS ± LABA
were similar, so we were able to compare these medica-
tions in a prospective observational design. Our results
suggest that tiotropium may be associated with decreased
exacerbations compared with ICS ± LABA among patients
without concurrent asthma. However a randomized clin-
ical trial would be needed to confirm this hypothesis.
Conclusions
In summary, this study examined risk factors for future
exacerbations in COPD subjects using common medica-
tions, which may help providers identify individuals at
higher risk of exacerbations and influence treatment
strategies or discussions of action plans. We confirmed
previous associations of GERD and female gender with
exacerbation risk in certain subsets, and found that pre-
vious pneumonia, higher SGRQ scores, and gas trap-
ping on CT scans were risk factors for exacerbations in
subjects using certain medications. The head-to-head
analysis also showed a trend towards a reduced exacer-
bation risk with tiotropium compared to ICS ± LABA in
COPD subjects without concurrent asthma, which could
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be viewed as hypothesis-generating for a clinical trial. This
study may also add to the body of literature questioning the
added benefit of ICS in moderate to severe COPD.
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